Other
Rx only
PRESCRIBING INFORMATION
Acyclovir Ointment USP, 5%
Acyclovir was not teratogenic in the mouse, rabbit, or rat at exposures greatly in excess of human exposure. There are no adequate and well-controlled studies of systemic acyclovir in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemicacyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Systemic acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Mfd. by: Sun Pharma Canada Inc., Brampton, Ontario, Canada L6T 1C1
Dist. by:
Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512
Revised: August 2025
5263777-0825-01 422